secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001787306-22-000070
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q3 net loss $107.7M ($1.89/share); ZORYVE launch generates $0.7M revenue
--------------------------------------------------------------------------------

- Net product revenue of $0.7M from ZORYVE launch; about half from wholesaler inventory build.
- Net loss $107.7M ($1.89 per share) vs $57.0M ($1.14) YoY; Ducentis acquisition added $0.51 per share.
- R&D expenses $69.7M (incl. $30M Ducentis upfront); SG&A $35.5M on launch costs.
- Cash, equivalents, and marketable securities $478.2M; $162M from Aug 2022 public offering and $125M debt draw.
- Positive topline Phase 3 data for roflumilast foam in scalp/body psoriasis; enrollment completed in atopic dermatitis trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000070/0001787306-22-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000070/arqt-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001787306-22-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer